{"protocolSection": {"identificationModule": {"nctId": "NCT00789698", "orgStudyIdInfo": {"id": "D1050234"}, "organization": {"fullName": "Sumitomo Pharma America, Inc.", "class": "INDUSTRY"}, "briefTitle": "Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia", "officialTitle": "A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)", "acronym": "PEARL 3 Ext"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-12"}, "primaryCompletionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-11-10", "studyFirstSubmitQcDate": "2008-11-12", "studyFirstPostDateStruct": {"date": "2008-11-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-03-27", "resultsFirstSubmitQcDate": "2012-07-13", "resultsFirstPostDateStruct": {"date": "2012-08-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-19", "lastUpdatePostDateStruct": {"date": "2015-06-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sumitomo Pharma America, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia."}, "conditionsModule": {"conditions": ["Chronic Schizophrenia"], "keywords": ["Schizophrenia", "SM-13496", "Latuda", "Lurasidone"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 240, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lurasidone HC1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Lurasidone HC1"]}, {"label": "Quetiapine", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Quetiapine XR"]}], "interventions": [{"type": "DRUG", "name": "Lurasidone HC1", "description": "Lurasidone 40-160 mg/day flexibly dosed.", "armGroupLabels": ["Lurasidone HC1"]}, {"type": "DRUG", "name": "Quetiapine XR", "description": "Quetiapine XR 200-800 mg/day flexibly dosed.", "armGroupLabels": ["Quetiapine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Relapse of Psychotic Symptoms", "description": "Time to relapse will be defined as the earliest occurrence of any of the following:\n\n* Worsening of \\>= 30% positive and negative syndrome scale total score from NCT00790192 and clinical global impression-severity sub-scale \\>=3\n* rehospitalization for worsening of psychosis\n* emergence of suicidal ideation, homicidal ideation and/or risk of harm to self or others Comparison of time to relapse of psychotic symptoms between lurasidone and quetiapine XR after 1 year as analyzed using the Cox proportional hazard model with country as a covariate.", "timeFrame": "12 Months"}], "secondaryOutcomes": [{"measure": "Change From the Acute Phase Baseline to Month 6 of the Double-blind Treatment in the CogState Computerized Cognitive Scores.", "description": "The battery has seven outcome measures that measure the cognitive constructs. The seven domains are: detection, identification, one back task, international shopping list task, one card learning task, Groton maze learning task and social emotional matching. The standardized scores for each subject at each assessment will then be averaged to yield a composite score. There are no maximum or minimum values, however a higher score indicates improved performance on the cognitive constructs. The change score is change from baseline to month 6.", "timeFrame": "Baseline and 6 Months"}, {"measure": "Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Positive and Negative Syndrome Scale (PANSS)", "description": "The PANSS is an interview-based measure of psychopathology severity in adults with psychotic disorders. Thirty items are rated using a Likert scale, from 1 - 7. The PANSS total score is the sum of thirty items ranging from 30 to 210 (higher score representing a worsening in psychosis).", "timeFrame": "Baseline and 12 months"}, {"measure": "Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Clinical Global Impression Severity Scale (CGI-S) Scores", "description": "The CGI-S is a clinician-rated assessment of the subject's current illness state on a scale ranging from 1-7, where a higher score is associated with greater illness severity.", "timeFrame": "Baseline and 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Entry Criteria:\n\n* Screening for the present study will take place after subjects' participation in Study D1050233 has been completed, and after providing informed consent.\n\nInclusion Criteria:\n\n* Completed all required assessments on the final study visit in Study D1050233.\n* Suitable for treatment in an outpatient setting.\n\nExclusion Criteria:\n\n* Any chronic organic disease of the CNS (other than schizophrenia).\n* Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director, MD", "affiliation": "Sumitomo Pharma America, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "K&S Professional Research Services, LLC", "city": "Little Rock", "state": "Arkansas", "zip": "72201", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Woodland International Research Group", "city": "Little Rock", "state": "Arkansas", "zip": "72211", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Comprehensive Neuroscience, Inc", "city": "Cerritos", "state": "California", "zip": "90703", "country": "United States", "geoPoint": {"lat": 33.85835, "lon": -118.06479}}, {"facility": "Clinical Innovations, Inc.", "city": "Costa Mesa", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Synergy Escondido,710 East Grand Ave.", "city": "Escondido", "state": "California", "zip": "92025", "country": "United States", "geoPoint": {"lat": 33.11921, "lon": -117.08642}}, {"facility": "Collaborative Neuroscience Network Inc", "city": "Garden Grove", "state": "California", "zip": "92645", "country": "United States", "geoPoint": {"lat": 33.77391, "lon": -117.94145}}, {"facility": "Apostle Clinical Trials, Inc.", "city": "Long Beach", "state": "California", "zip": "90813", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "California Clinical Trials", "city": "Paramount", "state": "California", "zip": "90723", "country": "United States", "geoPoint": {"lat": 33.88946, "lon": -118.15979}}, {"facility": "Pasadena Research Institute", "city": "Pasadena", "state": "California", "zip": "91107", "country": "United States", "geoPoint": {"lat": 34.14778, "lon": -118.14452}}, {"facility": "CNRI - Los Angeles LLC,8309 Telegraph Road", "city": "Pico Rivera", "state": "California", "zip": "90660", "country": "United States", "geoPoint": {"lat": 33.98307, "lon": -118.09673}}, {"facility": "CNRI- LOs Angeles, LLC", "city": "Pico Rivera", "state": "California", "zip": "90660", "country": "United States", "geoPoint": {"lat": 33.98307, "lon": -118.09673}}, {"facility": "Clinical Innovations, Inc.", "city": "Riverside", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "CNRI - San Diego", "city": "San Diego", "state": "California", "zip": "92102", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "UCSD Medical Drive", "city": "Sandeigo", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Segal Institute for Clinical Research", "city": "Highlands Ranch", "state": "Colorado", "zip": "80103", "country": "United States", "geoPoint": {"lat": 39.55388, "lon": -104.96943}}, {"facility": "Comprehensive Neuroscience, Inc.", "city": "Washington", "state": "District of Columbia", "zip": "20016", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Florida Clinical Research Center LLC", "city": "Bradenton", "state": "Florida", "zip": "34208", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"facility": "Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340", "city": "Lake Charles", "state": "Louisiana", "zip": "70601", "country": "United States", "geoPoint": {"lat": 30.21309, "lon": -93.2044}}, {"facility": "Booker, J. Gary, MD. APMC", "city": "Shreveport", "state": "Louisiana", "zip": "71104", "country": "United States", "geoPoint": {"lat": 32.52515, "lon": -93.75018}}, {"facility": "St. Charles Psychiatric Associates", "city": "St. Charles", "state": "Missouri", "zip": "63301", "country": "United States", "geoPoint": {"lat": 38.78394, "lon": -90.48123}}, {"facility": "St. Louis Research, Inc.", "city": "St. Louis", "state": "Missouri", "zip": "63118", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "CRI Worldwide", "city": "Willingboro", "state": "New Jersey", "zip": "08046", "country": "United States", "geoPoint": {"lat": 40.02789, "lon": -74.86905}}, {"facility": "SUNY Downstate Medical Center", "city": "Brooklyn", "state": "New York", "zip": "11238", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Comprehensive Neuroscience, Inc", "city": "Holliswood", "state": "New York", "zip": "11423", "country": "United States", "geoPoint": {"lat": 40.71344, "lon": -73.76708}}, {"facility": "Community Clinical Research", "city": "Austin", "state": "Texas", "zip": "78729", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "FutureSearch Clinical Trials, LLC.", "city": "Austin", "state": "Texas", "zip": "78756", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Pillar Clinical Research", "city": "Dallas", "state": "Texas", "zip": "75243", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "CIPNA Centro de Investigaciones y Proyectos en Neurociencias", "city": "Calle 80#47-43 Consultorio 5C", "state": "Barranquila S/N", "country": "Colombia"}, {"facility": "Centro de Investigacion y Atencion para la Salud Mental", "city": "Calle 103A # 21-49", "state": "Bogota S/N", "country": "Colombia"}, {"facility": "Centro de Investigaciones y Proyectos en Neurociencias CIPNA", "city": "Barranquilla", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Centro de Investigaci\u00f3n y Atenci\u00f3n para la Salud Mental", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "CISNE - UIC Campo Abierto", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Instituto Colombiano del Sistema Nervioso Cl\u00ednica Montserrat", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Vijayawada Institute of Mental Health and Neurosciences", "city": "Vijayawada", "state": "Andhra Pradesh", "zip": "520002", "country": "India", "geoPoint": {"lat": 16.50745, "lon": 80.6466}}, {"facility": "S.V. Medical College", "city": "Tirupati", "state": "Andra Pradesh", "zip": "517507", "country": "India", "geoPoint": {"lat": 13.63551, "lon": 79.41989}}, {"facility": "Shanti Nursing Home", "city": "Kanchanpalli", "state": "Aurangabad, Maharashtra", "country": "India"}, {"facility": "Seth K M School of P G Medicine & Research", "city": "Ahmedabad", "state": "Gujarat", "zip": "380006", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "SBKS Medical College and Hospital, Brij Psychiatry Hospital", "city": "Vadodara", "state": "Gujarat", "zip": "390001", "country": "India", "geoPoint": {"lat": 22.29941, "lon": 73.20812}}, {"facility": "Justice K.S. Hedge Charitable Hospital", "city": "Mangalore", "state": "Karna", "zip": "574160", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "JSS Medical College and Hospital - Dept of Psychiatry", "city": "Mysore", "state": "Karna", "zip": "570004", "country": "India", "geoPoint": {"lat": 12.29791, "lon": 76.63925}}, {"facility": "Mahatma Gandhi Institute of Medical Sciences", "city": "Sewagram", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 20.73578, "lon": 78.65911}}, {"facility": "Deenanath Mangeshkar Hospital and Research Centre", "city": "Pune", "state": "Maharastra", "zip": "411004", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Madras Medical College & Government General Hospital", "city": "Chennai", "state": "TamilNadu", "zip": "600003", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Spitalul Clinic Judetean de Urgenta Arad", "city": "Str. Octavian Goga nr. 17", "state": "Arad", "zip": "310022", "country": "Romania"}, {"facility": "Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia", "city": "Sos. Berceni nr. 10-12", "state": "Bucuresti", "zip": "041914", "country": "Romania"}, {"facility": "Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia", "city": "Bucuresti", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Spitalul Clinic de Neurologie si Psihiatrie Oradea", "city": "Oradea", "country": "Romania", "geoPoint": {"lat": 47.0458, "lon": 21.91833}}, {"facility": "Spitalul Judetean Arges", "city": "Pitesti", "zip": "110069", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"facility": "Andreev, Boris", "city": "Gatchina", "country": "Russian Federation", "geoPoint": {"lat": 59.57639, "lon": 30.12833}}, {"facility": "Gurovich, Isaak", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Morozova, Margarita", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Sheifer, Mikhail", "city": "Samara", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "City Psychoneurological Dispensary #7 (with Hospital)", "city": "St-Petersburg", "zip": "190005", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City Psyhiatric Hospital #2 of St. Nikolay Chudotvorets", "city": "St. Petersburg", "zip": "190121", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City Psychiatric Hospital #4", "city": "St. Petersburg", "zip": "191119", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City Psychiatric Hospital #3 of Skvortsov-Stepanov", "city": "St. Petersburg", "zip": "197341", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Neznanov, Nikolay", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Dnipropetrovsk Regional Clinical Hospital named Mechnikov", "city": "Dnipropetrovsk", "zip": "49005", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Reg.Clin.Psychiatric Hosp., Dept. #11, DSMU n.af.M.Gorkiy", "city": "Donetsk", "zip": "83037", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Kyiv City Clin. Psychoneurolog. Hosp.#1", "city": "Kyiv", "zip": "04080", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Kyiv City Psychoneurological Hospital", "city": "Kyviv", "country": "Ukraine"}, {"facility": "Lviv Reg.St.Cl.Psych.Hosp", "city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Reg. Psychiatric Hospital", "city": "Odessa", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Crimean republican Clinical Psychiatric Hospital", "city": "Simferopol", "country": "Ukraine", "geoPoint": {"lat": 44.95719, "lon": 34.11079}}, {"facility": "Kherson Regional Psychiatric Hospital", "city": "vil. Stepanovka, Kherson", "zip": "73488", "country": "Ukraine"}]}, "referencesModule": {"references": [{"pmid": "23583011", "type": "RESULT", "citation": "Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013 Jun;147(1):95-102. doi: 10.1016/j.schres.2013.03.013. Epub 2013 Apr 11."}, {"pmid": "24035633", "type": "RESULT", "citation": "Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013 Nov;23(11):1373-82. doi: 10.1016/j.euroneuro.2013.08.003. Epub 2013 Aug 27."}, {"pmid": "26117157", "type": "DERIVED", "citation": "Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res. 2015 Aug;166(1-3):334-8. doi: 10.1016/j.schres.2015.06.008. Epub 2015 Jun 24."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients transitioned from the acute phase study (D1050233 -NCT00790192) to the current study (D1050234) in a non-randomized fashion.", "groups": [{"id": "FG000", "title": "Lurasidone 80mg", "description": "Lurasidone 80mg/day in the acute phase study and flexibly-dosed lurasidone (40mg/day to 160mg/day) in the current study."}, {"id": "FG001", "title": "Lurasidone 160 mg", "description": "Lurasidone 160mg/day in the acute phase study and flexibly-dosed lurasidone (40mg/day to 160mg/day) in the current study."}, {"id": "FG002", "title": "Placebo-Lurasidone", "description": "Placebo in the acute phase study and flexibly-dosed lurasidone (40 mg/day to 160 mg/day) in the current study"}, {"id": "FG003", "title": "Quetiapine-Quetiapine", "description": "Quetiapine XR 600 mg/day in the acute phase study and flexibly-dosed quetiapine XR (200 mg/day to 800 mg/day) in the current study"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "72"}, {"groupId": "FG001", "numSubjects": "79"}, {"groupId": "FG002", "numSubjects": "56"}, {"groupId": "FG003", "numSubjects": "85"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "46"}, {"groupId": "FG002", "numSubjects": "29"}, {"groupId": "FG003", "numSubjects": "33"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "33"}, {"groupId": "FG002", "numSubjects": "27"}, {"groupId": "FG003", "numSubjects": "52"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "18"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "19"}]}, {"type": "Administrative", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Lurasidone 80mg", "description": "Lurasidone 80mg/day in the acute phase study and flexibly-dosed lurasidone (40mg/day to 160mg/day) in the current study."}, {"id": "BG001", "title": "Lurasidone 160 mg", "description": "Lurasidone 160mg/day in the acute phase study and flexibly-dosed lurasidone (40mg/day to 160mg/day) in the current study."}, {"id": "BG002", "title": "Placebo-Lurasidone", "description": "Placebo in the acute phase study and flexibly-dosed lurasidone (40 mg/day to 160 mg/day) in the current study"}, {"id": "BG003", "title": "Quetiapine-Quetiapine", "description": "Quetiapine XR 600 mg/day in the acute phase study and flexibly-dosed quetiapine XR (200 mg/day to 800 mg/day) in the current study"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "85"}, {"groupId": "BG004", "value": "292"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.6", "spread": "11.7"}, {"groupId": "BG001", "value": "37.6", "spread": "11.7"}, {"groupId": "BG002", "value": "37.5", "spread": "11.4"}, {"groupId": "BG003", "value": "38.5", "spread": "10.4"}, {"groupId": "BG004", "value": "37.6", "spread": "11.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "33"}, {"groupId": "BG004", "value": "97"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "52"}, {"groupId": "BG004", "value": "195"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "23"}, {"groupId": "BG004", "value": "70"}]}]}, {"title": "Ukraine", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "18"}, {"groupId": "BG004", "value": "59"}]}]}, {"title": "Romania", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "10"}, {"groupId": "BG004", "value": "27"}]}]}, {"title": "Russian Federation", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "17"}, {"groupId": "BG004", "value": "55"}]}]}, {"title": "Colombia", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "15"}]}]}, {"title": "India", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "13"}, {"groupId": "BG004", "value": "66"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Relapse of Psychotic Symptoms", "description": "Time to relapse will be defined as the earliest occurrence of any of the following:\n\n* Worsening of \\>= 30% positive and negative syndrome scale total score from NCT00790192 and clinical global impression-severity sub-scale \\>=3\n* rehospitalization for worsening of psychosis\n* emergence of suicidal ideation, homicidal ideation and/or risk of harm to self or others Comparison of time to relapse of psychotic symptoms between lurasidone and quetiapine XR after 1 year as analyzed using the Cox proportional hazard model with country as a covariate.", "populationDescription": "The population for relapse analyses is the relapse population which consists of those subjects who are enrolled in the present study, demonstrated response to 6 weeks of treatment with either lurasidone or quetiapine XR in study D1050233-NCT 00790192, and who took at least one dose of study medication in the present study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 Months", "groups": [{"id": "OG000", "title": "Lurasidone-Lurasidone", "description": "Lurasidone 80 mg/day or lurasidone 160 mg/day in the acute phase study and flexibly-dosed lurasidone (40 mg/day to 160 mg/day) in the current study."}, {"id": "OG001", "title": "Quetiapine-Quetiapine", "description": "Quetiapine XR 600 mg/day in the acute phase study and flexibly-dosed quetiapine XR (200 mg/day to 800 mg/day) in the current study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "21", "lowerLimit": "1", "upperLimit": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of time to relapse of psychotic symptoms between LUR-LUR and QXR-QXR as analyzed using the Cox proportional-hazards model.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "This is a non-inferiority analysis. Lurasidone will be declared as effective as quetiapine XR in preventing relapse if the upper bound of a 2-sided 95% confidence limit for the hazard ration of lurasidone vs. quetiapine is no greater than an equivalence hazard ratio margin of 1.93.", "pValueComment": "There is no hypothesis tested. Since this was a non-inferiority study, the upper bound of the 95% CI for the hazard ratio was compared to the pre-specified margin of 1.93 to demonstrate the non-inferiority of lurasidone compared to Quetiapine XR.", "statisticalMethod": "COX Proportional Hazards Model", "paramType": "Hazard Ratio (HR)", "paramValue": "0.728", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.410", "ciUpperLimit": "1.295"}]}, {"type": "SECONDARY", "title": "Change From the Acute Phase Baseline to Month 6 of the Double-blind Treatment in the CogState Computerized Cognitive Scores.", "description": "The battery has seven outcome measures that measure the cognitive constructs. The seven domains are: detection, identification, one back task, international shopping list task, one card learning task, Groton maze learning task and social emotional matching. The standardized scores for each subject at each assessment will then be averaged to yield a composite score. There are no maximum or minimum values, however a higher score indicates improved performance on the cognitive constructs. The change score is change from baseline to month 6.", "populationDescription": "The population is the intent to treat population which consists of those enrolled subjects who receive at least one dose of study medication and have either a PANSS or CGI-S baseline and post baseline measurements", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 6 Months", "groups": [{"id": "OG000", "title": "Lurasidone-Lurasidone", "description": "Lurasidone 80 mg/day or Lurasidone 160 mg/day in the acute phase study and flexibly-dosed lurasidone (40 mg/day to 160 mg/day) in the current study."}, {"id": "OG001", "title": "Quetiapine-Quetiapine", "description": "Quetiapine XR 600 mg/day in the acute phase study and flexibly-dosed quetiapine XR (200 mg/day to 800 mg/day) in the current study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "lowerLimit": "0.06", "upperLimit": "0.38"}, {"groupId": "OG001", "value": "-0.03", "lowerLimit": "-0.26", "upperLimit": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Positive and Negative Syndrome Scale (PANSS)", "description": "The PANSS is an interview-based measure of psychopathology severity in adults with psychotic disorders. Thirty items are rated using a Likert scale, from 1 - 7. The PANSS total score is the sum of thirty items ranging from 30 to 210 (higher score representing a worsening in psychosis).", "populationDescription": "The population is the intent to treat population which consists of those enrolled subjects who receive at least one dose of study medication and have either a PANSS or CGI-S baseline and post baseline measurements", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 12 months", "groups": [{"id": "OG000", "title": "Lurasidone-Lurasidone", "description": "Lurasidone 80 mg/day or lurasidone 160 mg/day in the acute phase study and flexibly-dosed lurasidone (40 mg/day to 160 mg/day) in the current study."}, {"id": "OG001", "title": "Quetiapine-Quetiapine", "description": "Quetiapine XR 600 mg/day in the acute phase study and flexibly-dosed quetiapine XR (200 mg/day to 800 mg/day) in the current study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "72"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-34.6", "lowerLimit": "-38.3", "upperLimit": "-30.9"}, {"groupId": "OG001", "value": "-25.7", "lowerLimit": "-30.9", "upperLimit": "-20.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Clinical Global Impression Severity Scale (CGI-S) Scores", "description": "The CGI-S is a clinician-rated assessment of the subject's current illness state on a scale ranging from 1-7, where a higher score is associated with greater illness severity.", "populationDescription": "The population is the intent to treat population which consists of those enrolled subjects who receive at least one dose of study medication and have either a PANSS or CGI-S baseline and post baseline measurements", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 12 months", "groups": [{"id": "OG000", "title": "Lurasidone-Lurasidone", "description": "Lurasidone 80 mg/day or lurasidone 160 mg/day in the acute phase study and flexibly-dosed lurasidone (40 mg/day to 160 mg/day) in the current study."}, {"id": "OG001", "title": "Quetiapine-Quetiapine", "description": "Quetiapine XR 600 mg/day in the acute phase study and flexibly-dosed quetiapine XR (200 mg/day to 800 mg/day) in the current study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "72"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9", "lowerLimit": "-2.1", "upperLimit": "-1.7"}, {"groupId": "OG001", "value": "-1.6", "lowerLimit": "-1.9", "upperLimit": "-1.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Lurasidone 80mg", "description": "Lurasidone 80mg/day in the acute phase study and flexibly-dosed lurasidone (40mg/day to 160mg/day) in the current study.", "seriousNumAffected": 9, "seriousNumAtRisk": 72, "otherNumAffected": 44, "otherNumAtRisk": 72}, {"id": "EG001", "title": "Lurasidone 160 mg", "description": "Lurasidone 160mg/day in the acute phase study and flexibly-dosed lurasidone (40mg/day to 160mg/day) in the current study.", "seriousNumAffected": 6, "seriousNumAtRisk": 79, "otherNumAffected": 51, "otherNumAtRisk": 79}, {"id": "EG002", "title": "Placebo-Lurasidone", "description": "Placebo in the acute phase study and flexibly-dosed lurasidone (40 mg/day to 160 mg/day) in the current study", "seriousNumAffected": 2, "seriousNumAtRisk": 56, "otherNumAffected": 35, "otherNumAtRisk": 56}, {"id": "EG003", "title": "Quetiapine-Quetiapine", "description": "Quetiapine XR 600 mg/day in the acute phase study and flexibly-dosed quetiapine XR (200 mg/day to 800 mg/day) in the current study", "seriousNumAffected": 17, "seriousNumAtRisk": 85, "otherNumAffected": 53, "otherNumAtRisk": 85}], "seriousEvents": [{"term": "Acute Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 85}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 85}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}, {"term": "Lower Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}, {"term": "Skeletal Injury", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}, {"term": "Parkinsonism", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 85}]}, {"term": "Completed Suicide", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}, {"term": "Psychotic Disorder", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 6, "numAffected": 6, "numAtRisk": 85}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 9, "numAffected": 9, "numAtRisk": 85}]}, {"term": "Schizophrenia, paranoid type", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}, {"term": "Suicidal Behavior", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 85}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 85}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 5, "numAffected": 3, "numAtRisk": 85}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 7, "numAffected": 4, "numAtRisk": 85}]}, {"term": "Weight Increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 8, "numAffected": 7, "numAtRisk": 85}]}, {"term": "Akathisia", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 11, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 9, "numAffected": 6, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 85}]}, {"term": "Dystonia", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 6, "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 85}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 16, "numAffected": 11, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 5, "numAffected": 3, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 11, "numAffected": 8, "numAtRisk": 85}]}, {"term": "Parkinsonism", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 12, "numAffected": 9, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 85}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 85}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 85}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 9, "numAffected": 8, "numAtRisk": 85}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 79}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 56}, {"groupId": "EG003", "numEvents": 16, "numAffected": 13, "numAtRisk": 85}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "In addition to the \\<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish."}, "pointOfContact": {"title": "Medical Director, CNS", "organization": "Sunovion Pharmaceuticals", "phone": "1-866-503-6351"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069348", "term": "Quetiapine Fumarate"}, {"id": "D000069056", "term": "Lurasidone Hydrochloride"}], "ancestors": [{"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000058669", "term": "Adrenergic alpha-2 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000058830", "term": "Serotonin 5-HT2 Receptor Antagonists"}, {"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000065127", "term": "Dopamine D2 Receptor Antagonists"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}], "browseLeaves": [{"id": "M348", "name": "Lurasidone Hydrochloride", "asFound": "Proton Pump", "relevance": "HIGH"}, {"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29195", "name": "Adrenergic alpha-2 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}